TherapeuticsMD Announces Second Quarter 2025 Financial Results
Trade with 70% Backtested Accuracy
Analyst Views on TXMD
About TXMD
About the author
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
TherapeuticsMD Swings to Profit in Q2
Financial Performance: TherapeuticsMD reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss of $1.05 million in the same quarter last year, driven by increased license revenue which rose to $1.0 million and a 45.5% reduction in operating expenses.
Business Model Transition: The company has fully transitioned to a royalty-focused business model, relying on licensing agreements with partners like Mayne Pharma for revenue, while ceasing its own research and development efforts, leading to a focus on cash preservation and operational efficiency.
TherapeuticsMD Q2 Earnings Summary
Earnings Performance: TherapeuticsMD reported earnings of $0.55 million in Q2, a significant improvement from a loss of $1.05 million in the same quarter last year.
Earnings Per Share (EPS): The company achieved an EPS of $0.05 in Q2, compared to a loss of $0.09 per share during the same period last year.
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.
Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Market Overview: The Dow Jones index rose over 450 points, indicating positive market sentiment, while insider trading activities in penny stocks reflect investor confidence or concerns regarding company prospects.
Recent Insider Transactions: Notable insider purchases include System1's Cee Holdings Trust acquiring shares after strong earnings, TherapeuticsMD's director buying shares following a quarterly loss, and Ault Alliance's executive purchasing shares amid dividend announcements.
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q2 2024
Earnings Report: TherapeuticsMD (NASDAQ:TXMD) reported a second quarter 2024 earnings per share of -9 cents and revenue of $234,000.
Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick access to key financial figures without human intervention.
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
- Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
- Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
- Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
- Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
TherapeuticsMD Swings to Profit in Q2
Financial Performance: TherapeuticsMD reported a net income of $545 thousand for Q2 2025, a significant improvement from a loss of $1.05 million in the same quarter last year, driven by increased license revenue which rose to $1.0 million and a 45.5% reduction in operating expenses.
Business Model Transition: The company has fully transitioned to a royalty-focused business model, relying on licensing agreements with partners like Mayne Pharma for revenue, while ceasing its own research and development efforts, leading to a focus on cash preservation and operational efficiency.
TherapeuticsMD Q2 Earnings Summary
Earnings Performance: TherapeuticsMD reported earnings of $0.55 million in Q2, a significant improvement from a loss of $1.05 million in the same quarter last year.
Earnings Per Share (EPS): The company achieved an EPS of $0.05 in Q2, compared to a loss of $0.09 per share during the same period last year.
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
GameStop Earnings Report: GameStop Corp. shares rose 13.4% in pre-market trading after reporting fourth-quarter adjusted earnings of 30 cents per share, exceeding analyst expectations, despite revenue falling short of estimates at $1.283 billion.
Pre-Market Stock Movements: Several stocks saw significant gains in pre-market trading, including Theratechnologies Inc. (+88.3%) and SurgePays, Inc. (+69.5%), while others like Golden Heaven Group Holdings Ltd. (-24.4%) and Humacyte, Inc. (-22.1%) experienced notable declines.
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Market Overview: The Dow Jones index rose over 450 points, indicating positive market sentiment, while insider trading activities in penny stocks reflect investor confidence or concerns regarding company prospects.
Recent Insider Transactions: Notable insider purchases include System1's Cee Holdings Trust acquiring shares after strong earnings, TherapeuticsMD's director buying shares following a quarterly loss, and Ault Alliance's executive purchasing shares amid dividend announcements.
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q2 2024
Earnings Report: TherapeuticsMD (NASDAQ:TXMD) reported a second quarter 2024 earnings per share of -9 cents and revenue of $234,000.
Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick access to key financial figures without human intervention.
